Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmPACT Bio USA

https://immpact-bio.com/

Latest From ImmPACT Bio USA

EHA Preview: ASCO Overlap Gives Smaller Companies Chance To Shine

Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.

Clinical Trials Commercial

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.

Financing Immune Disorders

Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E

Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.

Financing Innovation

Deal Watch: Ikena Cuts Staff After BMS Exits IO Partnership

Plus deals involving Lipocine/Verity, Vivtex/AI Proteins, Windtree/Lee’s Pharmaceutical, Biogen/Ji Xing, Sermonix/Henlius and news from the world of technology transfer.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register